HESI Midpoint Exam V1 | 150 Questions & Answers with
Rationales | 2026/2027 Edition | Complete A+ Guide
HESI Midpoint Exam V1 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide contains 150 verified questions and answers with detailed rationales
for the HESI Midpoint Exam V1. Designed to help nursing students achieve a top score, the document
covers all key content areas tested on the exam, including medical-surgical nursing, pharmacology,
maternal-child health, and more. Each question is accompanied by a rationale explaining the correct
answer and distractor analysis, ensuring deep understanding. Updated for the 2026/2027 academic
year, this guide reflects the latest HESI exam blueprint and clinical guidelines.
Key Features:
150 verified HESI Midpoint Exam V1 questions with rationales
Comprehensive coverage of medical-surgical, pharmacology, maternal-child, and psychiatric nursing
Detailed rationales for correct answers and distractor explanations
Updated to reflect 2026/2027 HESI exam guidelines and clinical standards
Organized by content area with question ranges and weight percentages
Ideal for final review and self-assessment before the exam
Updates for 2026:
- Incorporated latest NCLEX-RN and HESI test plan changes for 2026/2027
- Revised rationales to include current evidence-based practice guidelines
- Added new questions on emerging topics such as telehealth and COVID-19 management
- Updated pharmacology content to reflect new drug approvals and safety alerts
Abstract:
The HESI Midpoint Exam V1 is a critical assessment for nursing students, evaluating their knowledge and clinical
reasoning skills midway through their program. This study guide provides 150 meticulously selected questions that
mirror the exam's format and difficulty. Each question is paired with a comprehensive rationale that not only
explains the correct answer but also analyzes common distractors, reinforcing key concepts. The content is
organized into major nursing domains: medical-surgical nursing (40%), pharmacology (20%), maternal-child
health (15%), psychiatric nursing (15%), and professional issues (10%). Updated for the 2026/2027 academic
year, this resource aligns with the latest HESI exam blueprint and incorporates current clinical guidelines. By
mastering these questions, students can identify knowledge gaps, build confidence, and achieve a high score on the
exam. This guide is an essential tool for nursing students seeking to excel in their mid-program evaluation.
Keywords:
HESI Midpoint Exam, Nursing exam prep, 150 questions with rationales, 2026/2027 study guide, Medical-surgical
nursing, Pharmacology, Maternal-child health, Psychiatric nursing
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct. Distractor
options are analyzed to clarify common misconceptions. Rationales are written in a clear, concise manner to
facilitate learning and retention.
Compliance Checklist:
All questions verified against HESI Midpoint Exam V1 blueprint
Rationales updated to reflect 2026/2027 clinical guidelines
Content organized by nursing domain with weight percentages
Page 1
, Distractor explanations included for each question
Suitable for self-assessment and final review
Content Area Overview:
Content Area Questions Key Topics Weight
Medical-Surgical Nursing 1-60 Cardiovascular, Respiratory, 40%
Gastrointestinal, Endocrine, Renal
Pharmacology 61-90 Drug classifications, Dosage calculations, 20%
Adverse effects, Interactions
Maternal-Child Health 91-112 Prenatal care, Labor and delivery, Newborn 15%
care, Pediatric growth and development
Psychiatric Nursing 113-137 Therapeutic communication, Mental health 15%
disorders, Psychopharmacology, Crisis
intervention
Professional Issues 138-150 Ethics, Legal issues, Delegation, Quality 10%
improvement
Page 2
,Q1. A 45-year-old patient with a history of type 2 diabetes and chronic kidney disease (stage 3) is admitted
with hyperkalemia (K+ 6.2 mEq/L) and metabolic acidosis (pH 7.28, HCO3- 16 mEq/L, PaCO2 34 mm Hg).
Which of the following interventions addresses both the hyperkalemia and the acidosis via a single
mechanism?
A. Intravenous calcium gluconate
B. Inhaled albuterol
C. Intravenous sodium bicarbonate
D. Intravenous insulin with dextrose
Correct Answer: C. Intravenous sodium bicarbonate
Rationale: Sodium bicarbonate directly buffers excess hydrogen ions, shifting the acidosis, and promotes
intracellular shift of potassium as pH rises, lowering serum K+. Calcium gluconate only stabilizes cardiac
membranes. Albuterol shifts K+ but does not correct acidosis. Insulin with dextrose shifts K+ but does not address
acidosis.
Why Wrong:
A - Calcium gluconate protects the heart but does not lower potassium or correct acidosis.
B - Albuterol lowers potassium via beta-2 stimulation but does not affect acidosis.
D - Insulin with dextrose shifts potassium intracellularly but does not correct metabolic acidosis.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52, 54
Q2. Which of the following best describes the primary reason that angiotensin-converting enzyme inhibitors
(ACEIs) are preferred over angiotensin II receptor blockers (ARBs) in patients with heart failure and
reduced ejection fraction (HFrEF) who also have chronic kidney disease?
A. ACEIs provide more complete blockade of the renin-angiotensin-aldosterone system (RAAS)
B. ACEIs have a superior side-effect profile regarding hyperkalemia
C. ACEIs increase bradykinin levels, which may confer additional cardioprotective effects
D. ACEIs are less likely to cause acute kidney injury in this population
Correct Answer: C. ACEIs increase bradykinin levels, which may confer additional cardioprotective effects
Rationale: ACEIs inhibit both angiotensin II formation and bradykinin degradation. Increased bradykinin
promotes vasodilation and may have additional cardioprotective effects beyond RAAS blockade. ARBs only block
angiotensin II at the receptor. Both can cause hyperkalemia and AKI; ACEIs are not superior in side-effect profile
or completeness of RAAS blockade (ARBs can also block via AT1 receptor).
Why Wrong:
A - ACEIs and ARBs both effectively block RAAS; ARBs block angiotensin II at the receptor, which may be
more complete in some tissues.
B - Both classes carry similar risk of hyperkalemia; no clear superiority.
D - Both classes can reduce GFR; ACEIs are not less nephrotoxic.
Reference: Yancy, C.W., et al. (2024). ACC/AHA/HFSA Guideline for the Management of Heart Failure. J Am Coll
Cardiol.
Q3. A patient with acute respiratory distress syndrome (ARDS) is on volume-controlled mechanical
ventilation. Plateau pressure is 32 cm H2O, and PaO2/FiO2 ratio is 150. Which of the following ventilator
adjustments is most appropriate to reduce ventilator-induced lung injury while maintaining oxygenation?
A. Increase PEEP to 20 cm H2O and reduce tidal volume to 4 mL/kg predicted body weight
B. Increase respiratory rate to 35 breaths/min and keep tidal volume at 6 mL/kg
C. Switch to pressure-controlled ventilation with a driving pressure of 20 cm H2O
D. Administer a neuromuscular blocking agent and prone positioning without ventilator changes
Correct Answer: A. Increase PEEP to 20 cm H2O and reduce tidal volume to 4 mL/kg predicted body weight
Rationale: High plateau pressure (>30 cm H2O) indicates risk of volutrauma/barotrauma. Reducing tidal volume
(to 4 mL/kg) and increasing PEEP can reduce plateau pressure while maintaining recruitment and oxygenation.
Page 3
, Option B increases minute ventilation but does not address plateau pressure. Option C may not guarantee volume.
Option D is adjunctive but does not directly modify ventilator settings.
Why Wrong:
B - Increasing rate does not lower plateau pressure; may worsen dynamic hyperinflation.
C - Pressure-controlled ventilation does not ensure adequate tidal volume; plateau pressure may still be high.
D - Neuromuscular blockade and proning are adjuncts but do not replace lung-protective ventilation.
Reference: ARDS Network (2000). N Engl J Med; 342:1301-1308. Updated guidelines (2025).
Q4. A patient with a history of recurrent Clostridioides difficile infection (rCDI) is being evaluated for fecal
microbiota transplantation (FMT). Which of the following is a contraindication to FMT according to current
guidelines?
A. Recent use of oral vancomycin for acute CDI
B. History of inflammatory bowel disease (IBD)
C. Severe immunosuppression including neutropenia
D. Age greater than 65 years
Correct Answer: C. Severe immunosuppression including neutropenia
Rationale: Severe immunosuppression (e.g., neutropenia, solid organ transplant recipients) is a contraindication
due to risk of translocation of donor microbes and sepsis. Recent vancomycin use is common before FMT. IBD is
not an absolute contraindication but requires caution. Age >65 is not a contraindication.
Why Wrong:
A - Vancomycin is often discontinued shortly before FMT; it is not a contraindication.
B - IBD is a relative caution but not an absolute contraindication.
D - Elderly patients frequently receive FMT; age alone is not a contraindication.
Reference: McDonald, L.C., et al. (2024). Clinical Practice Guidelines for Clostridioides difficile Infection. IDSA.
Q5. Which of the following best explains why the therapeutic index of lithium is narrow, requiring regular
monitoring of serum levels?
A. Lithium has a high volume of distribution and accumulates in bone tissue
B. Lithium is extensively protein-bound and displaces other drugs
C. Lithium is reabsorbed in the proximal tubule, and small changes in sodium balance alter its clearance
significantly
D. Lithium undergoes extensive hepatic first-pass metabolism, leading to variable bioavailability
Correct Answer: C. Lithium is reabsorbed in the proximal tubule, and small changes in sodium balance alter
its clearance significantly
Rationale: Lithium is freely filtered and reabsorbed in the proximal tubule. Sodium depletion increases lithium
reabsorption, raising levels. Conversely, sodium loading increases excretion. This sensitivity, combined with a
narrow therapeutic window (0.6-1.2 mEq/L), necessitates monitoring. Lithium is not protein-bound, does not
accumulate in bone, and is not metabolized.
Why Wrong:
A - Lithium does not significantly accumulate in bone; it distributes in total body water.
B - Lithium is not protein-bound; it is freely filtered.
D - Lithium is not metabolized; it is excreted renally unchanged.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 8.
Q6. A patient with a known penicillin allergy (reported hives 10 years ago) requires intravenous antibiotics
for a confirmed Streptococcus pyogenes necrotizing fasciitis. Which of the following is the most appropriate
antibiotic choice?
A. Ceftriaxone
B. Clindamycin
Page 4
Rationales | 2026/2027 Edition | Complete A+ Guide
HESI Midpoint Exam V1 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide contains 150 verified questions and answers with detailed rationales
for the HESI Midpoint Exam V1. Designed to help nursing students achieve a top score, the document
covers all key content areas tested on the exam, including medical-surgical nursing, pharmacology,
maternal-child health, and more. Each question is accompanied by a rationale explaining the correct
answer and distractor analysis, ensuring deep understanding. Updated for the 2026/2027 academic
year, this guide reflects the latest HESI exam blueprint and clinical guidelines.
Key Features:
150 verified HESI Midpoint Exam V1 questions with rationales
Comprehensive coverage of medical-surgical, pharmacology, maternal-child, and psychiatric nursing
Detailed rationales for correct answers and distractor explanations
Updated to reflect 2026/2027 HESI exam guidelines and clinical standards
Organized by content area with question ranges and weight percentages
Ideal for final review and self-assessment before the exam
Updates for 2026:
- Incorporated latest NCLEX-RN and HESI test plan changes for 2026/2027
- Revised rationales to include current evidence-based practice guidelines
- Added new questions on emerging topics such as telehealth and COVID-19 management
- Updated pharmacology content to reflect new drug approvals and safety alerts
Abstract:
The HESI Midpoint Exam V1 is a critical assessment for nursing students, evaluating their knowledge and clinical
reasoning skills midway through their program. This study guide provides 150 meticulously selected questions that
mirror the exam's format and difficulty. Each question is paired with a comprehensive rationale that not only
explains the correct answer but also analyzes common distractors, reinforcing key concepts. The content is
organized into major nursing domains: medical-surgical nursing (40%), pharmacology (20%), maternal-child
health (15%), psychiatric nursing (15%), and professional issues (10%). Updated for the 2026/2027 academic
year, this resource aligns with the latest HESI exam blueprint and incorporates current clinical guidelines. By
mastering these questions, students can identify knowledge gaps, build confidence, and achieve a high score on the
exam. This guide is an essential tool for nursing students seeking to excel in their mid-program evaluation.
Keywords:
HESI Midpoint Exam, Nursing exam prep, 150 questions with rationales, 2026/2027 study guide, Medical-surgical
nursing, Pharmacology, Maternal-child health, Psychiatric nursing
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct. Distractor
options are analyzed to clarify common misconceptions. Rationales are written in a clear, concise manner to
facilitate learning and retention.
Compliance Checklist:
All questions verified against HESI Midpoint Exam V1 blueprint
Rationales updated to reflect 2026/2027 clinical guidelines
Content organized by nursing domain with weight percentages
Page 1
, Distractor explanations included for each question
Suitable for self-assessment and final review
Content Area Overview:
Content Area Questions Key Topics Weight
Medical-Surgical Nursing 1-60 Cardiovascular, Respiratory, 40%
Gastrointestinal, Endocrine, Renal
Pharmacology 61-90 Drug classifications, Dosage calculations, 20%
Adverse effects, Interactions
Maternal-Child Health 91-112 Prenatal care, Labor and delivery, Newborn 15%
care, Pediatric growth and development
Psychiatric Nursing 113-137 Therapeutic communication, Mental health 15%
disorders, Psychopharmacology, Crisis
intervention
Professional Issues 138-150 Ethics, Legal issues, Delegation, Quality 10%
improvement
Page 2
,Q1. A 45-year-old patient with a history of type 2 diabetes and chronic kidney disease (stage 3) is admitted
with hyperkalemia (K+ 6.2 mEq/L) and metabolic acidosis (pH 7.28, HCO3- 16 mEq/L, PaCO2 34 mm Hg).
Which of the following interventions addresses both the hyperkalemia and the acidosis via a single
mechanism?
A. Intravenous calcium gluconate
B. Inhaled albuterol
C. Intravenous sodium bicarbonate
D. Intravenous insulin with dextrose
Correct Answer: C. Intravenous sodium bicarbonate
Rationale: Sodium bicarbonate directly buffers excess hydrogen ions, shifting the acidosis, and promotes
intracellular shift of potassium as pH rises, lowering serum K+. Calcium gluconate only stabilizes cardiac
membranes. Albuterol shifts K+ but does not correct acidosis. Insulin with dextrose shifts K+ but does not address
acidosis.
Why Wrong:
A - Calcium gluconate protects the heart but does not lower potassium or correct acidosis.
B - Albuterol lowers potassium via beta-2 stimulation but does not affect acidosis.
D - Insulin with dextrose shifts potassium intracellularly but does not correct metabolic acidosis.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52, 54
Q2. Which of the following best describes the primary reason that angiotensin-converting enzyme inhibitors
(ACEIs) are preferred over angiotensin II receptor blockers (ARBs) in patients with heart failure and
reduced ejection fraction (HFrEF) who also have chronic kidney disease?
A. ACEIs provide more complete blockade of the renin-angiotensin-aldosterone system (RAAS)
B. ACEIs have a superior side-effect profile regarding hyperkalemia
C. ACEIs increase bradykinin levels, which may confer additional cardioprotective effects
D. ACEIs are less likely to cause acute kidney injury in this population
Correct Answer: C. ACEIs increase bradykinin levels, which may confer additional cardioprotective effects
Rationale: ACEIs inhibit both angiotensin II formation and bradykinin degradation. Increased bradykinin
promotes vasodilation and may have additional cardioprotective effects beyond RAAS blockade. ARBs only block
angiotensin II at the receptor. Both can cause hyperkalemia and AKI; ACEIs are not superior in side-effect profile
or completeness of RAAS blockade (ARBs can also block via AT1 receptor).
Why Wrong:
A - ACEIs and ARBs both effectively block RAAS; ARBs block angiotensin II at the receptor, which may be
more complete in some tissues.
B - Both classes carry similar risk of hyperkalemia; no clear superiority.
D - Both classes can reduce GFR; ACEIs are not less nephrotoxic.
Reference: Yancy, C.W., et al. (2024). ACC/AHA/HFSA Guideline for the Management of Heart Failure. J Am Coll
Cardiol.
Q3. A patient with acute respiratory distress syndrome (ARDS) is on volume-controlled mechanical
ventilation. Plateau pressure is 32 cm H2O, and PaO2/FiO2 ratio is 150. Which of the following ventilator
adjustments is most appropriate to reduce ventilator-induced lung injury while maintaining oxygenation?
A. Increase PEEP to 20 cm H2O and reduce tidal volume to 4 mL/kg predicted body weight
B. Increase respiratory rate to 35 breaths/min and keep tidal volume at 6 mL/kg
C. Switch to pressure-controlled ventilation with a driving pressure of 20 cm H2O
D. Administer a neuromuscular blocking agent and prone positioning without ventilator changes
Correct Answer: A. Increase PEEP to 20 cm H2O and reduce tidal volume to 4 mL/kg predicted body weight
Rationale: High plateau pressure (>30 cm H2O) indicates risk of volutrauma/barotrauma. Reducing tidal volume
(to 4 mL/kg) and increasing PEEP can reduce plateau pressure while maintaining recruitment and oxygenation.
Page 3
, Option B increases minute ventilation but does not address plateau pressure. Option C may not guarantee volume.
Option D is adjunctive but does not directly modify ventilator settings.
Why Wrong:
B - Increasing rate does not lower plateau pressure; may worsen dynamic hyperinflation.
C - Pressure-controlled ventilation does not ensure adequate tidal volume; plateau pressure may still be high.
D - Neuromuscular blockade and proning are adjuncts but do not replace lung-protective ventilation.
Reference: ARDS Network (2000). N Engl J Med; 342:1301-1308. Updated guidelines (2025).
Q4. A patient with a history of recurrent Clostridioides difficile infection (rCDI) is being evaluated for fecal
microbiota transplantation (FMT). Which of the following is a contraindication to FMT according to current
guidelines?
A. Recent use of oral vancomycin for acute CDI
B. History of inflammatory bowel disease (IBD)
C. Severe immunosuppression including neutropenia
D. Age greater than 65 years
Correct Answer: C. Severe immunosuppression including neutropenia
Rationale: Severe immunosuppression (e.g., neutropenia, solid organ transplant recipients) is a contraindication
due to risk of translocation of donor microbes and sepsis. Recent vancomycin use is common before FMT. IBD is
not an absolute contraindication but requires caution. Age >65 is not a contraindication.
Why Wrong:
A - Vancomycin is often discontinued shortly before FMT; it is not a contraindication.
B - IBD is a relative caution but not an absolute contraindication.
D - Elderly patients frequently receive FMT; age alone is not a contraindication.
Reference: McDonald, L.C., et al. (2024). Clinical Practice Guidelines for Clostridioides difficile Infection. IDSA.
Q5. Which of the following best explains why the therapeutic index of lithium is narrow, requiring regular
monitoring of serum levels?
A. Lithium has a high volume of distribution and accumulates in bone tissue
B. Lithium is extensively protein-bound and displaces other drugs
C. Lithium is reabsorbed in the proximal tubule, and small changes in sodium balance alter its clearance
significantly
D. Lithium undergoes extensive hepatic first-pass metabolism, leading to variable bioavailability
Correct Answer: C. Lithium is reabsorbed in the proximal tubule, and small changes in sodium balance alter
its clearance significantly
Rationale: Lithium is freely filtered and reabsorbed in the proximal tubule. Sodium depletion increases lithium
reabsorption, raising levels. Conversely, sodium loading increases excretion. This sensitivity, combined with a
narrow therapeutic window (0.6-1.2 mEq/L), necessitates monitoring. Lithium is not protein-bound, does not
accumulate in bone, and is not metabolized.
Why Wrong:
A - Lithium does not significantly accumulate in bone; it distributes in total body water.
B - Lithium is not protein-bound; it is freely filtered.
D - Lithium is not metabolized; it is excreted renally unchanged.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 8.
Q6. A patient with a known penicillin allergy (reported hives 10 years ago) requires intravenous antibiotics
for a confirmed Streptococcus pyogenes necrotizing fasciitis. Which of the following is the most appropriate
antibiotic choice?
A. Ceftriaxone
B. Clindamycin
Page 4
